For research use only. Not medical advice.
Overview
Tesamorelin is a synthetic 44–amino acid GHRH analog that stimulates endogenous GH release and raises IGF-1 levels.
It is FDA-approved for reducing visceral fat and is widely researched for body composition, metabolic enhancement, and aging-related applications.
Most research follows the standard 2 mg once-daily subcutaneous protocol.
Daily Dosing Protocol (Subcutaneous)
Standard Daily Dose
2 mg once daily
Administered consistently at the same time each day (often in the evening to align with nocturnal GH rhythms).
Optional Titration Schedule
Some researchers prefer to begin with a short ramp to improve tolerability.
Week 1
1 mg daily
Weeks 2–12+
2 mg daily
This is the typical working and maintenance dose used in clinical and research settings.
Cycle Length
While Tesamorelin can be used continuously, the most common research patterns are:
8–12 weeks on protocol, followed by
2–4 weeks off, then repeat as needed.
Longer continuous use (12–24+ weeks) is also documented in research settings.
Alternate Timing Strategies
Although daily evening administration is the classic model, researchers may use morning Dosing
Chosen when subjects report improved energy or reduced nighttime hunger signals.
Split Dosing
1 mg twice daily
Used occasionally to blunt injection-site reactions or flatten GH spikes.
View the vendor profile: 
